Figure S1.

## Efficacy Endpoint: HIV-1 RNA <50 c/mL\*

Study 103 - Primary (Wk 48) and Secondary (Wk 96 and 144)




Figure S2.

## Difference in Efficacy by Subgroup

Study 103 – Week 144

		STB (n=353)	ATV/RTV+FTC/TDF (n=355)	Favors ATV/RTV+FTC/TDF Favors STB
OVERALL		78%	75%	- •
AGE (yrs)	<40	76%	69%	•
	≥40	80%	81%	
SEX	Male	80%	76%	
	Female	52%	62%	•
RACE	White	81%	75%	•
	Nonwhite	69%	73%	
BL HIV-1 RNA	≤ 100K c/mL	79%	77%	
	> 100K c/mL	75%	72%	•
BL CD4	≤ 350 cells/µL	76%	74%	
	> 350 cells/µL	80%	75%	
Adherence	< 95%	59%	66%	
	≥ 95%	85%	79%	-30 -20 -10 0 10 20 3